Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1778538,relative bio-availability,"The dose-corrected relative bio-availability of acebutolol was not different from 100% on day 1 and day 10; however the dose-corrected diacetolol AUC, SR/conventional ratio, was significantly lower than 100% on days 1 and 10.",A comparative pharmacokinetic and pharmacodynamic study of conventional and sustained-release preparations of acebutolol in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778538/),%,100,13095,DB01193,Acebutolol
lower,1778538,AUC,"The dose-corrected relative bio-availability of acebutolol was not different from 100% on day 1 and day 10; however the dose-corrected diacetolol AUC, SR/conventional ratio, was significantly lower than 100% on days 1 and 10.",A comparative pharmacokinetic and pharmacodynamic study of conventional and sustained-release preparations of acebutolol in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778538/),%,100,13096,DB01193,Acebutolol
,1269192,distribution half-life (T 1/2D),"From the intravenous data (obtained up to 6 hr after dosing), the following mean (+/-SD) values were found: distribution half-life (T 1/2D), 0.60 (+/-0.43) hr, plasma elimination half-life (T 1/2El), 3.2 (+/-1.1) hr, apparent volume of distribution (VD), 224 (+/-69) L, and apparent VD/kg, 3.0 (+/-0.8) L/kg.",Observations on the pharmacokinetics of acebutolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),h,0.60,21598,DB01193,Acebutolol
,1269192,plasma elimination half-life (T 1/2El),"From the intravenous data (obtained up to 6 hr after dosing), the following mean (+/-SD) values were found: distribution half-life (T 1/2D), 0.60 (+/-0.43) hr, plasma elimination half-life (T 1/2El), 3.2 (+/-1.1) hr, apparent volume of distribution (VD), 224 (+/-69) L, and apparent VD/kg, 3.0 (+/-0.8) L/kg.",Observations on the pharmacokinetics of acebutolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),h,3.2,21599,DB01193,Acebutolol
,1269192,apparent volume of distribution (VD),"From the intravenous data (obtained up to 6 hr after dosing), the following mean (+/-SD) values were found: distribution half-life (T 1/2D), 0.60 (+/-0.43) hr, plasma elimination half-life (T 1/2El), 3.2 (+/-1.1) hr, apparent volume of distribution (VD), 224 (+/-69) L, and apparent VD/kg, 3.0 (+/-0.8) L/kg.",Observations on the pharmacokinetics of acebutolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),l,224,21600,DB01193,Acebutolol
,1269192,apparent VD/kg,"From the intravenous data (obtained up to 6 hr after dosing), the following mean (+/-SD) values were found: distribution half-life (T 1/2D), 0.60 (+/-0.43) hr, plasma elimination half-life (T 1/2El), 3.2 (+/-1.1) hr, apparent volume of distribution (VD), 224 (+/-69) L, and apparent VD/kg, 3.0 (+/-0.8) L/kg.",Observations on the pharmacokinetics of acebutolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),[l] / [kg],3.0,21601,DB01193,Acebutolol
,1269192,T 1/2El,"Using the oral data (obtained up to 10 hr after dosing), the value for T 1/2El was 3.2 (+/-0.9) hr.",Observations on the pharmacokinetics of acebutolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),h,3.2,21602,DB01193,Acebutolol
,1269192,cumulative urinary recovery,"The mean cumulative urinary recovery (expressed as % dose) after the intravenous route was about 60%, while that after the oral route was of the order of 35%, suggesting that about half of the oral dose reached the systemic circulation.",Observations on the pharmacokinetics of acebutolol. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),%,60,21603,DB01193,Acebutolol
,1269192,cumulative urinary recovery,"The mean cumulative urinary recovery (expressed as % dose) after the intravenous route was about 60%, while that after the oral route was of the order of 35%, suggesting that about half of the oral dose reached the systemic circulation.",Observations on the pharmacokinetics of acebutolol. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),%,35,21604,DB01193,Acebutolol
,1269192,renal clearance,"The mean creatinine clearance of the 6 subjects was 103 (+/-7) ml/min, while the value (obtained between 2 and 4 hr after intravenous dosing) for renal clearance of acebutolol as measured was 298 (+/-68) ml/min and the corresponding plasma clearance was 818 (+/-64) ml/min.",Observations on the pharmacokinetics of acebutolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),[ml] / [min],298,21605,DB01193,Acebutolol
,1269192,plasma clearance,"The mean creatinine clearance of the 6 subjects was 103 (+/-7) ml/min, while the value (obtained between 2 and 4 hr after intravenous dosing) for renal clearance of acebutolol as measured was 298 (+/-68) ml/min and the corresponding plasma clearance was 818 (+/-64) ml/min.",Observations on the pharmacokinetics of acebutolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269192/),[ml] / [min],818,21606,DB01193,Acebutolol
,6884417,AUC,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],4492,42619,DB01193,Acebutolol
,6884417,AUC,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],4118,42620,DB01193,Acebutolol
,6884417,half-life,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"7,69",42621,DB01193,Acebutolol
,6884417,half-life,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"8,10",42622,DB01193,Acebutolol
,6884417,renal clearance,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"13,1",42623,DB01193,Acebutolol
,6884417,renal clearance,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"13,8",42624,DB01193,Acebutolol
,6884417,AUC,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],784,42625,DB01193,Acebutolol
,6884417,AUC,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],720,42626,DB01193,Acebutolol
,6884417,t 1/2,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"4,79",42627,DB01193,Acebutolol
,6884417,t 1/2,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"4,73",42628,DB01193,Acebutolol
,6884417,renal clearance,"The renal clearance was slightly higher when HCT was given with acebutolol (26,2 +/- 2,6 vs 20,3 +/- 2,1 lh-1, p less than 0,05).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"26,2",42629,DB01193,Acebutolol
,6884417,renal clearance,"The renal clearance was slightly higher when HCT was given with acebutolol (26,2 +/- 2,6 vs 20,3 +/- 2,1 lh-1, p less than 0,05).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"20,3",42630,DB01193,Acebutolol
,6151871,brain:plasma uptake ratio,"Propranolol, by far the most lipophilic beta-blocker in vitro, had the highest in vivo metabolic clearance and volume of distribution (Vd), the most rapid entry into CSF, and the highest brain:plasma uptake ratio (38.0).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,38.0,44818,DB01193,Acebutolol
,6151871,brain:plasma ratio,"Sotalol, the most hydrophilic drug in vitro, had the lowest in vivo clearance and Vd, the slowest CSF entry, and the lowest brain:plasma ratio (0.52).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.52,44819,DB01193,Acebutolol
,6151871,brain:plasma uptake ratio,"Acebutolol had slightly greater in vitro lipophilicity than sotalol, intermediate values of in vivo plasma kinetics and CSF entry rate, and a slightly greater brain:plasma uptake ratio (0.71).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.71,44820,DB01193,Acebutolol
,8721279,flow rate,"The drugs and the internal standard (acebutolol) were eluted from a 4-microns Novapak C-18 cartridge at ambient temperature with an isocratic mobile phase consisting of 14% acetonitrile in buffer solution, at a flow rate of 2.5 ml/min.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),[ml] / [min],2.5,57099,DB01193,Acebutolol
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,105.5,57100,DB01193,Acebutolol
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,99.5,57101,DB01193,Acebutolol
,9210978,R:S,"The amount of R-DC recovered in urine, however, was greater than that of the antipode (R:S = 1.92 +/- 0.29).",Pharmacokinetics of acebutolol enantiomers after intravenous administration of racemate in a rat model: a dosing range comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210978/),,1.92,58699,DB01193,Acebutolol
,6852547,apparent volume of distribution,"After intravenous administration, apparent volume of distribution (1.5 vs.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),,1.5,82251,DB01193,Acebutolol
,6852547,total body clearance,"2.4 liter . kg-1, p less than 0.05) and total body clearance (6.2 vs. 8.8 ml . min-1 . kg-1, n.s.) of acebutolol are smaller in elderly than in young men.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),[ml] / [kg·min],6.2,82252,DB01193,Acebutolol
,6852547,total body clearance,"2.4 liter . kg-1, p less than 0.05) and total body clearance (6.2 vs. 8.8 ml . min-1 . kg-1, n.s.) of acebutolol are smaller in elderly than in young men.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),[ml] / [kg·min],8.8,82253,DB01193,Acebutolol
,6852547,maximum plasma levels,"After oral administration, maximum plasma levels (28.03 vs. 9.68 micrograms . l-1 . kg-1) and area under the curve (163.1 vs.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),[μg] / [kg·l],28.03,82254,DB01193,Acebutolol
,6852547,maximum plasma levels,"After oral administration, maximum plasma levels (28.03 vs. 9.68 micrograms . l-1 . kg-1) and area under the curve (163.1 vs.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),[μg] / [kg·l],9.68,82255,DB01193,Acebutolol
,6852547,area under the curve,"After oral administration, maximum plasma levels (28.03 vs. 9.68 micrograms . l-1 . kg-1) and area under the curve (163.1 vs.",A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),,163.1,82256,DB01193,Acebutolol
,6852547,plasma half-lives,Acebutolol and diacetolol plasma half-lives increase in elderly patients (11.6 vs. 7.2 h and 14.8 vs. 12 h respectively).,A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),h,11.6,82257,DB01193,Acebutolol
,6852547,plasma half-lives,Acebutolol and diacetolol plasma half-lives increase in elderly patients (11.6 vs. 7.2 h and 14.8 vs. 12 h respectively).,A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),h,7.2,82258,DB01193,Acebutolol
,6852547,plasma half-lives,Acebutolol and diacetolol plasma half-lives increase in elderly patients (11.6 vs. 7.2 h and 14.8 vs. 12 h respectively).,A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),h,14.8,82259,DB01193,Acebutolol
,6852547,plasma half-lives,Acebutolol and diacetolol plasma half-lives increase in elderly patients (11.6 vs. 7.2 h and 14.8 vs. 12 h respectively).,A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6852547/),h,12,82260,DB01193,Acebutolol
,23435913,flow rate,"The chromatographic separation was performed on a reverse phase C18 column with a mobile phase consisting of 0.1 % formic acid and acetonitrile (45:55, v/v) at a flow rate of 0.3 mL/min.",Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435913/),[ml] / [min],0.3,95219,DB01193,Acebutolol
,12877562,area under the plasma concentration-time curve from time zero to time infinity,"After oral administration of acebutolol to acute and chronic groups, the plasma concentrations appeared higher; As a result, area under the plasma concentration-time curve from time zero to time infinity10575 and 8668 microg x h/mL for acute and chronic group, respectively.",Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877562/),[h·μg] / [ml],10575,145066,DB01193,Acebutolol
,12877562,area under the plasma concentration-time curve from time zero to time infinity,"After oral administration of acebutolol to acute and chronic groups, the plasma concentrations appeared higher; As a result, area under the plasma concentration-time curve from time zero to time infinity10575 and 8668 microg x h/mL for acute and chronic group, respectively.",Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877562/),[h·μg] / [ml],8668,145067,DB01193,Acebutolol
,12877562,area,"In comparison, the area was apparently smaller in the control group (i.e., 7132 microg x h/mL).",Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877562/),[h·μg] / [ml],7132,145068,DB01193,Acebutolol
,12877562,half-life,"The half-life in acute groups was significantly prolonged 8.45 h compared with the half-life in the control group (i.e., 6.30 h).",Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877562/),h,8.45,145069,DB01193,Acebutolol
,12877562,half-life,"The half-life in acute groups was significantly prolonged 8.45 h compared with the half-life in the control group (i.e., 6.30 h).",Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877562/),h,6.30,145070,DB01193,Acebutolol
,7286031,oral bioavailability,"The average oral bioavailability of diacetolol was F: 0.302 +/- 0.052 (100 mg), 0.363 +/- 0.052 (400 mg) and 0.426 +/- 0.068 (800 mg); the differences are not significant.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),,0.302,150889,DB01193,Acebutolol
,7286031,oral bioavailability,"The average oral bioavailability of diacetolol was F: 0.302 +/- 0.052 (100 mg), 0.363 +/- 0.052 (400 mg) and 0.426 +/- 0.068 (800 mg); the differences are not significant.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),,0.363,150890,DB01193,Acebutolol
,7286031,oral bioavailability,"The average oral bioavailability of diacetolol was F: 0.302 +/- 0.052 (100 mg), 0.363 +/- 0.052 (400 mg) and 0.426 +/- 0.068 (800 mg); the differences are not significant.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),,0.426,150891,DB01193,Acebutolol
,7286031,plasma half-life of the terminal phase,"The mean plasma half-life of the terminal phase, 7.94 +/- 0.26 h after intravenous administration, was significantly higher than after oral administration 12.27 +/- 1.00 h (100 mg), 12.82 +/- 1.59 h (400 mg) and 13.05 +/- 13.05 +/- 1.22 h (800 mg) (p less than 0.02 to 0.05); the mean urine half-lives of the terminal phase were not significantly different.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),h,7.94,150892,DB01193,Acebutolol
,7286031,plasma half-life of the terminal phase,"The mean plasma half-life of the terminal phase, 7.94 +/- 0.26 h after intravenous administration, was significantly higher than after oral administration 12.27 +/- 1.00 h (100 mg), 12.82 +/- 1.59 h (400 mg) and 13.05 +/- 13.05 +/- 1.22 h (800 mg) (p less than 0.02 to 0.05); the mean urine half-lives of the terminal phase were not significantly different.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),h,12.27,150893,DB01193,Acebutolol
,7286031,plasma half-life of the terminal phase,"The mean plasma half-life of the terminal phase, 7.94 +/- 0.26 h after intravenous administration, was significantly higher than after oral administration 12.27 +/- 1.00 h (100 mg), 12.82 +/- 1.59 h (400 mg) and 13.05 +/- 13.05 +/- 1.22 h (800 mg) (p less than 0.02 to 0.05); the mean urine half-lives of the terminal phase were not significantly different.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),h,12.82,150894,DB01193,Acebutolol
,7286031,plasma half-life of the terminal phase,"The mean plasma half-life of the terminal phase, 7.94 +/- 0.26 h after intravenous administration, was significantly higher than after oral administration 12.27 +/- 1.00 h (100 mg), 12.82 +/- 1.59 h (400 mg) and 13.05 +/- 13.05 +/- 1.22 h (800 mg) (p less than 0.02 to 0.05); the mean urine half-lives of the terminal phase were not significantly different.","Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),h,13.05,150895,DB01193,Acebutolol
,7286031,Renal clearance,Renal clearance of diacetolol 10.2 +/- 0.81 . h-1 represented about wo-thirds of total body clearance 15.9 +/- 1.21 . h-1.,"Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),1/[h],10.2,150896,DB01193,Acebutolol
,7286031,total body clearance,Renal clearance of diacetolol 10.2 +/- 0.81 . h-1 represented about wo-thirds of total body clearance 15.9 +/- 1.21 . h-1.,"Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286031/),1/[h],15.9,150897,DB01193,Acebutolol
,1295378,protein binding,The limited protein binding of AC (10%) was neither stereoselective nor affected by AA.,Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1295378/),%,10,153507,DB01193,Acebutolol
,16305592,peak plasma concentration (Cmax),"Grapefruit juice decreased the peak plasma concentration (Cmax) of acebutolol by 19% from 872 +/- 207 ng mL(-1) to 706 +/- 140 ng mL(-1) (95% CI on the difference -306, -26.4; P < 0.05), and the area under the concentration time curve (AUC(0-33 h)) by 7%, from 4498 +/- 939 ng mL(-1) h to 4182 +/- 915 ng mL(-1) h (95% CI -609, -23.0; P < 0.05).",Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),[ng] / [ml],872,160983,DB01193,Acebutolol
,16305592,peak plasma concentration (Cmax),"Grapefruit juice decreased the peak plasma concentration (Cmax) of acebutolol by 19% from 872 +/- 207 ng mL(-1) to 706 +/- 140 ng mL(-1) (95% CI on the difference -306, -26.4; P < 0.05), and the area under the concentration time curve (AUC(0-33 h)) by 7%, from 4498 +/- 939 ng mL(-1) h to 4182 +/- 915 ng mL(-1) h (95% CI -609, -23.0; P < 0.05).",Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),[ng] / [ml],706,160984,DB01193,Acebutolol
,16305592,area under the concentration time curve (AUC(0-33 h)),"Grapefruit juice decreased the peak plasma concentration (Cmax) of acebutolol by 19% from 872 +/- 207 ng mL(-1) to 706 +/- 140 ng mL(-1) (95% CI on the difference -306, -26.4; P < 0.05), and the area under the concentration time curve (AUC(0-33 h)) by 7%, from 4498 +/- 939 ng mL(-1) h to 4182 +/- 915 ng mL(-1) h (95% CI -609, -23.0; P < 0.05).",Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),[h·ng] / [ml],4498,160985,DB01193,Acebutolol
,16305592,area under the concentration time curve (AUC(0-33 h)),"Grapefruit juice decreased the peak plasma concentration (Cmax) of acebutolol by 19% from 872 +/- 207 ng mL(-1) to 706 +/- 140 ng mL(-1) (95% CI on the difference -306, -26.4; P < 0.05), and the area under the concentration time curve (AUC(0-33 h)) by 7%, from 4498 +/- 939 ng mL(-1) h to 4182 +/- 915 ng mL(-1) h (95% CI -609, -23.0; P < 0.05).",Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),[h·ng] / [ml],4182,160986,DB01193,Acebutolol
,16305592,half-life (t1/2),The half-life (t1/2) of acebutolol prolonged from 4.0 to 5.1 h (P < 0.05).,Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),h,4.,160987,DB01193,Acebutolol
,16305592,half-life (t1/2),The half-life (t1/2) of acebutolol prolonged from 4.0 to 5.1 h (P < 0.05).,Effects of grapefruit juice on the pharmacokinetics of acebutolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305592/),h,5,160988,DB01193,Acebutolol
,7248475,initial,"Mean initial and terminal half-lives of about 2 and 11 h, respectively, were determined.","The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248475/),h,2,186204,DB01193,Acebutolol
,7248475,terminal half-lives,"Mean initial and terminal half-lives of about 2 and 11 h, respectively, were determined.","The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248475/),h,11,186205,DB01193,Acebutolol
,1865329,AUC S:R,"Concentrations of S-AC were predominant in both plasma and urine [AUC S:R, 1.20 +/- 0.1; cumulative urinary excretion (sigma Xu) S:R, 1.17 +/- 0.05), which corresponded to a significantly greater oral clearance of R-AC (106 +/- 30 L/h) than S-AC (87 +/- 22 L/h).",Pharmacokinetics of acebutolol enantiomers in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),,1.20,211799,DB01193,Acebutolol
,1865329,cumulative urinary excretion (sigma Xu) S:R,"Concentrations of S-AC were predominant in both plasma and urine [AUC S:R, 1.20 +/- 0.1; cumulative urinary excretion (sigma Xu) S:R, 1.17 +/- 0.05), which corresponded to a significantly greater oral clearance of R-AC (106 +/- 30 L/h) than S-AC (87 +/- 22 L/h).",Pharmacokinetics of acebutolol enantiomers in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),,1.17,211800,DB01193,Acebutolol
,1865329,oral clearance,"Concentrations of S-AC were predominant in both plasma and urine [AUC S:R, 1.20 +/- 0.1; cumulative urinary excretion (sigma Xu) S:R, 1.17 +/- 0.05), which corresponded to a significantly greater oral clearance of R-AC (106 +/- 30 L/h) than S-AC (87 +/- 22 L/h).",Pharmacokinetics of acebutolol enantiomers in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),[l] / [h],106,211801,DB01193,Acebutolol
,1865329,oral clearance,"Concentrations of S-AC were predominant in both plasma and urine [AUC S:R, 1.20 +/- 0.1; cumulative urinary excretion (sigma Xu) S:R, 1.17 +/- 0.05), which corresponded to a significantly greater oral clearance of R-AC (106 +/- 30 L/h) than S-AC (87 +/- 22 L/h).",Pharmacokinetics of acebutolol enantiomers in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),[l] / [h],87,211802,DB01193,Acebutolol
,1865329,S/R,The Cmax of R-DC was significantly greater than for S-DC (S/R 0.7 +/- 0.1).,Pharmacokinetics of acebutolol enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),,0.7,211803,DB01193,Acebutolol
,1865329,half-life (t1/2),The half-life (t1/2) of R-DC (6.4 +/- 1.6 h) was significantly shorter than that of S-DC (8.8 +/- 2.4 h).,Pharmacokinetics of acebutolol enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),h,6.4,211804,DB01193,Acebutolol
,1865329,half-life (t1/2),The half-life (t1/2) of R-DC (6.4 +/- 1.6 h) was significantly shorter than that of S-DC (8.8 +/- 2.4 h).,Pharmacokinetics of acebutolol enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),h,8.8,211805,DB01193,Acebutolol
,1865329,Renal clearance,Renal clearance of R-DC (70 +/- 34 mL/min) was significantly greater than that of S-DC (53 +/- 29 mL/min).,Pharmacokinetics of acebutolol enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),[ml] / [min],70,211806,DB01193,Acebutolol
,1865329,Renal clearance,Renal clearance of R-DC (70 +/- 34 mL/min) was significantly greater than that of S-DC (53 +/- 29 mL/min).,Pharmacokinetics of acebutolol enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865329/),[ml] / [min],53,211807,DB01193,Acebutolol
,22889991,flow rate,"The separation was achieved with XBridge C18 column (150 mm × 3.0mm i.d., 3.5 μm) at 35 °C using a mixture of acetonitrile and 10mM ammonium acetate buffer (pH 10.5) (34:66, v/v) under isocratic conditions at a flow rate of 0.4 ml/min.",Determination of celiprolol in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22889991/),[ml] / [min],0.4,234400,DB01193,Acebutolol
,22889991,Retention times,"Retention times for the internal standard (acebutolol) and celiprolol were 4.2 min and 6.3 min, respectively.",Determination of celiprolol in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22889991/),min,4.2,234401,DB01193,Acebutolol
,22889991,Retention times,"Retention times for the internal standard (acebutolol) and celiprolol were 4.2 min and 6.3 min, respectively.",Determination of celiprolol in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22889991/),min,6.3,234402,DB01193,Acebutolol
,913023,blood clearance,"The mean blood clearance was 6.55 ml/min/kg and the mean renal clearance, 2.68 ml/min/kg.",Acebutolol disposition after intravenous administration. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),[ml] / [kg·min],6.55,237568,DB01193,Acebutolol
,913023,renal clearance,"The mean blood clearance was 6.55 ml/min/kg and the mean renal clearance, 2.68 ml/min/kg.",Acebutolol disposition after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),[ml] / [kg·min],2.68,237569,DB01193,Acebutolol
,913023,fast,"The mean fast and slow half-lives were 6.08 and 156.8 min, respectively.",Acebutolol disposition after intravenous administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),min,6.08,237570,DB01193,Acebutolol
,913023,slow half-lives,"The mean fast and slow half-lives were 6.08 and 156.8 min, respectively.",Acebutolol disposition after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),min,156.8,237571,DB01193,Acebutolol
,913023,volume of the central compartment,"The volume of the central compartment was 0.223 L/kg, and the volume of distribution at steady-state was 1.165 L/kg.",Acebutolol disposition after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),[l] / [kg],0.223,237572,DB01193,Acebutolol
,913023,volume of distribution at steady-state,"The volume of the central compartment was 0.223 L/kg, and the volume of distribution at steady-state was 1.165 L/kg.",Acebutolol disposition after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),[l] / [kg],1.165,237573,DB01193,Acebutolol
,913023,fraction of acebutolol unbound to plasma proteins,The fraction of acebutolol unbound to plasma proteins was 0.743 and was independent of drug concentration in the range examined.,Acebutolol disposition after intravenous administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/913023/),,0.743,237574,DB01193,Acebutolol
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,9.4,257759,DB01193,Acebutolol
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,13.2,257760,DB01193,Acebutolol
,768905,late biological half-life plasma,"In one of the patients treated by intravenous infusion (20 mg/10 mn), the late biological half-life plasma was calculated to be 7.5 h.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,7.5,257761,DB01193,Acebutolol
,768905,Renal clearance,Renal clearance of acebutolol was shown to be close to a mean of 83 ml plasma/mn for each of three patients (two oral and one intravenous) in spite of the fact that one of the orally treated patients had an elevated level of urea in his plasma (47 mg/100 ml) indicative of some impairment of kidney function.,[Pharmacokinetics of acebutolol]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),[ml·plasma] / [mn],83,257762,DB01193,Acebutolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,29,257763,DB01193,Acebutolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,64,257764,DB01193,Acebutolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,93,257765,DB01193,Acebutolol
,7140021,terminal elimination half-life,"Following chronic oral administration the mean terminal elimination half-life of unchanged acebutolol was about 10 hours independent of renal function, whereas the hall-life of the N-acetyl metabolite increased from 12.8 hr in subjects with normal renal function (GFR greater than 90 ml/min) to 24.0 hr in preuremic patients (GFR less than 10 ml/min).",The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140021/),h,10,261126,DB01193,Acebutolol
,7140021,hall-life,"Following chronic oral administration the mean terminal elimination half-life of unchanged acebutolol was about 10 hours independent of renal function, whereas the hall-life of the N-acetyl metabolite increased from 12.8 hr in subjects with normal renal function (GFR greater than 90 ml/min) to 24.0 hr in preuremic patients (GFR less than 10 ml/min).",The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140021/),h,12.8,261127,DB01193,Acebutolol
,7140021,hall-life,"Following chronic oral administration the mean terminal elimination half-life of unchanged acebutolol was about 10 hours independent of renal function, whereas the hall-life of the N-acetyl metabolite increased from 12.8 hr in subjects with normal renal function (GFR greater than 90 ml/min) to 24.0 hr in preuremic patients (GFR less than 10 ml/min).",The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140021/),h,24.0,261128,DB01193,Acebutolol
,7140021,area of the plasma level-time curve (AUC),The mean area of the plasma level-time curve (AUC) of the metabolite was 14.2 mg 1-1 hr in patients with normal renal function and rose to a value of 81.4 mg 1-1 hr in preuremic patients.,The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140021/),h·mg,14.2,261129,DB01193,Acebutolol
,7140021,area of the plasma level-time curve (AUC),The mean area of the plasma level-time curve (AUC) of the metabolite was 14.2 mg 1-1 hr in patients with normal renal function and rose to a value of 81.4 mg 1-1 hr in preuremic patients.,The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140021/),h·mg,81.4,261130,DB01193,Acebutolol
,1219629,dialysance,"The dialysance of acebutolol, in vitro, has been found to be equal to 87 ml/mn for a blood flow of 200 ml/mn through an artificial kidney; at the same flow rate, that of urea is 136 ml/mn.",[Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1219629/),[ml] / [mn],87,265778,DB01193,Acebutolol
,1219629,half-life,"In subjects with normal renal function, half-life of acebutolol in plasma, after oral administration, is 4.4 +/- 0.6 h; in haemodialysed patients with renal failure, it is very increased; during haemodialysis, it is near normal (mean: 5.9 h in 4 subjects).",[Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1219629/),h,4.4,265779,DB01193,Acebutolol
,1219629,half-life,"In subjects with normal renal function, half-life of acebutolol in plasma, after oral administration, is 4.4 +/- 0.6 h; in haemodialysed patients with renal failure, it is very increased; during haemodialysis, it is near normal (mean: 5.9 h in 4 subjects).",[Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1219629/),h,5.9,265780,DB01193,Acebutolol
,9818708,bioavailabilities,The bioavailabilities of R- and S-enantiomer were 0.40 and 0.39 after single dose administration of AC respectively.,Pharmacokinetics of single oral and multiple intravenous and oral administration of acebutolol enantiomers in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818708/),,0.40,266077,DB01193,Acebutolol
,9818708,bioavailabilities,The bioavailabilities of R- and S-enantiomer were 0.40 and 0.39 after single dose administration of AC respectively.,Pharmacokinetics of single oral and multiple intravenous and oral administration of acebutolol enantiomers in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818708/),,0.39,266078,DB01193,Acebutolol
